+39 02 610346.1 - info@newron.com

Investors and Media

Investors and Media

Newron Pharmaceuticals is headquartered in Bresso, Italy and its shares are listed on SIX Swiss Exchange under the ticker symbol NWRN. Newron is committed to providing reliable and transparent information about our business in an open and timely manner. This area contains investment and shareholder information, including our latest share price, key financial data and presentations and webcasts.

 

Newron newssee all

March 25 2017

Newron presents encouraging detailed results of its Phase IIa study with Evenamide in patients with schizophrenia

 

March 21 2017

FDA APPROVES XADAGO® (SAFINAMIDE) FOR PARKINSON’S DISEASE (PD) PATIENTS

 

March 16 2017

Newron to Present at the 16th International Congress on Schizophrenia Research

 

March 02 2017

Newron announces 2016 financial results and provides outlook for 2017 Board approves agenda for AGM on March 28, 2017

 

February 21 2017

Newron Supports Global Rare Disease Day® 2017 and Rett Syndrome Studies

 

Stock information

Download centre

Email alerts

 

 

 

 

 

Upcoming Eventssee all

Investora 2017

Sept. 20-21, 2017 - Zurich, CH

Jefferies 2017 Global Healthcare Conference

June 6-9, 2017 at the Grand Hyatt in New York City

Bio€quity Europe 2017

May 22-23 - Paris, France